Total Payments
$311,822
2024 Payments
$2,080
Companies
25
Transactions
198
Payment Breakdown by Category
Research$294,254 (94.4%)
Travel$11,466 (3.7%)
Food & Beverage$4,022 (1.3%)
Consulting$2,080 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $294,254 | 61 | 94.4% |
| Travel and Lodging | $11,466 | 36 | 3.7% |
| Food and Beverage | $4,022 | 100 | 1.3% |
| Consulting Fee | $2,080 | 1 | 0.7% |
Payments by Type
Research
$294,254
61 transactions
General
$17,569
137 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $290,178 | 30 | $0 (2018) |
| AstraZeneca UK Limited | $4,262 | 20 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $3,842 | 23 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,613 | 30 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $3,303 | 24 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $2,133 | 2 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $1,914 | 14 | $0 (2019) |
| AstraZeneca AB | $1,246 | 9 | $0 (2018) |
| Eli Lilly and Company | $462.95 | 1 | $0 (2020) |
| Respiratory Technologies, Inc. | $253.04 | 4 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,080 | 1 | Regeneron Pharmaceuticals, Inc. ($2,080) |
| 2022 | $53.13 | 1 | Regeneron Pharmaceuticals, Inc. ($53.13) |
| 2020 | $3,323 | 30 | Takeda Pharmaceuticals U.S.A., Inc. ($2,812) |
| 2019 | $6,137 | 33 | AstraZeneca UK Limited ($1,798) |
| 2018 | $49,508 | 34 | Glenmark Pharmaceuticals Inc. ($44,857) |
| 2017 | $250,721 | 99 | Glenmark Pharmaceuticals Inc. ($245,320) |
All Payment Transactions
198 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,080.00 | General |
| 07/28/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $53.13 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/29/2020 | Eli Lilly and Company | — | — | In-kind items and services | $462.95 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 09/24/2020 | Novartis Pharmaceuticals Corporation | XOLAIR (Biological) | Food and Beverage | In-kind items and services | $48.57 | General |
| Category: RESPIRATORY | ||||||
| 02/13/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $435.68 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/13/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $51.41 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/13/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $50.40 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/13/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $35.27 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/13/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $27.05 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/13/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $27.05 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/13/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $26.68 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/12/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $115.76 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/12/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $51.42 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/12/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $50.40 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/12/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $35.27 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/12/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $28.95 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/12/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $28.55 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/12/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $26.09 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/11/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $121.13 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 02/11/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $62.50 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 01/24/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $554.98 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | ||||||
| 01/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $74.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $25.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP304-201 | Glenmark Pharmaceuticals Inc. | $245,320 | 28 |
| Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Glenmark Pharmaceuticals Inc. | $44,857 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | Takeda Pharmaceuticals U.S.A., Inc. | $1,729 | 17 |
| A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | Takeda Pharmaceuticals U.S.A., Inc. | $1,083 | 11 |
| A Phase 1b Randomized, Double-blind, Placebo-Controlled, Crossover Study of 2 Single Intravenous Infusion Doses of TAK-925 in Subjects With Obstructive Sleep Apnea Who Are Experiencing Excessive Daytime Sleepiness Despite Adequate Use of CPAP | Takeda Pharmaceuticals U.S.A., Inc. | $801.82 | 2 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $462.95 | 1 |
About Dr. Faisal Fakih, MD
Dr. Faisal Fakih, MD is a Specialist healthcare provider based in Winter Park, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1386635480.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Faisal Fakih, MD has received a total of $311,822 in payments from pharmaceutical and medical device companies, with $2,080 received in 2024. These payments were reported across 198 transactions from 25 companies. The most common payment nature is "" ($294,254).
Ad
Practice Information
- Specialty Specialist
- Location Winter Park, FL
- Active Since 10/31/2005
- Last Updated 12/10/2012
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1386635480
Products in Payments
- MK-7264 (Drug) $1,890
- FASENRA (Drug) $1,341
- BEVESPI AEROSPHERE (Drug) $1,260
- FEVIPIPRANT (Drug) $1,164
- QBW251 (Drug) $621.24
- Prolastin-C (Biological) $118.46
- OFEV (Drug) $69.15
- DUPIXENT (Biological) $53.13
- PICO (Device) $52.29
- XOLAIR (Biological) $48.57
- RELISTOR (Drug) $46.84
- OPSUMIT MACITENTAN (Drug) $44.00
- GLASSIA (Biological) $40.73
- Esbriet (Biological) $33.61
- CHANTIX (Drug) $30.13
- Astral (Device) $28.88
- Xyrem (Drug) $19.46
- BREO (Drug) $16.59
- INCRUSE (Drug) $16.18
- SIVEXTRO (Drug) $14.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Winter Park
Dr. Paul Ziajka, Md, Phd, MD, PHD
Specialist — Payments: $150,712
Specialist $150,712
Dr. Donald Rotatori, M.d, M.D
Specialist — Payments: $14,104
Specialist $14,104
Dr. Brian Joseph, Md, MD
Specialist — Payments: $5,935
Specialist $5,935
Dr. Charles Koller, M.d, M.D
Specialist — Payments: $4,774
Specialist $4,774
Mrs. Aymar Rodriguez-Perez, M.d, M.D
Specialist — Payments: $2,017
Specialist $2,017
Dr. Roberto Posada, M.d, M.D
Specialist — Payments: $376.93
Specialist $376.93